Regenerative Medicine and Advanced Therapies: An Introduction
Distinguish between human cellular and tissue-based products (HCT/P). Review the regulatory framework for the regulation of regenerative medicine products and discuss key definitions and eligible therapies. Examine expedited programs for RMATs. Review emerging issues in gene editing, in-office procedures and stem cell manufacturing practices.
Joanne Hawana, Member, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
This session was recorded as part of FDLI’s Virtual Introduction to Biologics and Biosimilars Laws and Regulations Course in March/April 2020.
- +$100 for nonmembers
Virtual Learning FAQ
On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.
On-demand content can be played back on most devices.
If you have concerns, please click the Test Your System link to determine your device’s compatibility, as well as system requirements.
CLE credit is not currently available for pre-recorded sessions.